<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium thiosulfate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium thiosulfate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium thiosulfate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9939" href="/d/html/9939.html" rel="external">see "Sodium thiosulfate: Drug information"</a> and <a class="drug drug_patient" data-topicid="12124" href="/d/html/12124.html" rel="external">see "Sodium thiosulfate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57630511"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pedmark</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868268"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Seacalphyx</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062295"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Cyanide</span>;</li>
<li>
<span class="list-set-name">Antidote, Extravasation</span></li></ul></div>
<div class="block dop drugH1Div" id="F222309"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Parenteral sodium thiosulfate is available as two separate products with unique indications, concentrations, and dosing which should not be interchanged.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78acc119-232b-4ae3-8e06-979279be85ac">Cisplatin-induced ototoxicity; risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cisplatin-induced ototoxicity; risk reduction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients receiving cisplatin infusions ≤6 hours duration; with cisplatin infusions &gt;6 hours, irreversible ototoxicity may have already occurred and sodium thiosulfate may not reduce this risk. Prior to each sodium thiosulfate dose, administer antiemetic therapy and ensure that sodium level is within normal limits.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Pedmark (125 mg/mL solution):</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;5 kg: IV: 10 <b>g</b>/<b>m<sup>2</sup></b>/dose 6 hours after completion of each cisplatin infusion. <b>Note:</b> If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in &lt;10 hours, do not administer sodium thiosulfate. Refer to individual protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">5 to 10 kg: IV: 15 <b>g</b>/<b>m<sup>2</sup></b>/dose 6 hours after completion of each cisplatin infusion. <b>Note:</b> If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in &lt;10 hours, do not administer sodium thiosulfate. Refer to individual protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;10 kg: IV: 20 <b>g</b>/<b>m<sup>2</sup></b>/dose 6 hours after completion of each cisplatin infusion. <b>Note:</b> If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in &lt;10 hours, do not administer sodium thiosulfate. Refer to individual protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924955','lexi-content-ref-27914822','lexi-content-ref-31866182','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d45c167-1cac-4768-9b58-6250793d8421">Cyanide poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyanide poisoning:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Hydroxocobalamin is the preferred cyanide antidote; if hydroxocobalamin is unavailable, sodium nitrite may be used in conjunction with sodium thiosulfate. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). Dosing in pediatric patients is based on the 250 mg/mL (25%) solution and expressed in multiple units (mg/kg, mL/kg); use extra caution. Administer in conjunction with sodium nitrite. Consider consultation with a clinical toxicologist or poison control center.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: 250 mg/mL solution (25%): IV: 250 to 412.5 mg/kg (1 to 1.65 mL/kg of a 25% solution); maximum dose: 12.5 <b>g</b>/dose (50 mL of a 25% solution) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holstege.1','lexi-content-ref-Howland.1','lexi-content-ref-24196100','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holstege.1','lexi-content-ref-Howland.1','lexi-content-ref-24196100','lexi-content-ref-Manu.1'])">Ref</a></span>). Monitor patients for 24 to 48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1436790-f5af-43d5-8b15-c07cd41c0a01">Extravasation management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechlorethamine extravasation:</i> Children and Adolescents: SUBQ: 1/6 M (~4%) solution: Inject 2 mL for each mg of mechlorethamine suspected to have extravasated; administer immediately into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23304728','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23304728','lexi-content-ref-Polovich.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cisplatin extravasation, concentrated:</i> Infants, Children, and Adolescents: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation; may repeat SUBQ injections several times over the next 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cisplatin-induced ototoxicity; risk reduction:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Sodium thiosulfate (125 mg/mL): Pedmark: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption style="text-align:left;">
<b>Sodium Thiosulfate (Pedmark) Recommended Dosage Adjustments for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Adverse Reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dosage Modification</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Hypernatremia</p></td>
<td align="left">
<p style="text-indent:0em;">&gt;145 mmol/L</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold sodium thiosulfate (Pedmark) and administer supportive care as needed. When sodium is within normal limits, resume therapy at same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypokalemia</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold sodium thiosulfate (Pedmark) and supplement potassium as needed. When potassium is within normal limits, resume therapy at same dose.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Hypersensitivity reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 1 or 2</p></td>
<td align="left">
<p style="text-indent:0em;">Immediately stop sodium thiosulfate (Pedmark) infusion and administer appropriate care. Administer antihistamines or glucocorticoids (if appropriate) prior to subsequent doses.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3 or 4</p></td>
<td align="left">
<p style="text-indent:0em;">Immediately stop sodium thiosulfate (Pedmark) and administer appropriate care. Permanently discontinue sodium thiosulfate (Pedmark).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold sodium thiosulfate (Pedmark) until ≤ grade 1. Resume at the same dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue sodium thiosulfate (Pedmark).</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51160226"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51160227"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F222300"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9939" href="/d/html/9939.html" rel="external">see "Sodium thiosulfate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d45c167-1cac-4768-9b58-6250793d8421">Cyanide poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyanide poisoning (alternative agent): Note:</b> If hydroxocobalamin is unavailable, then sodium nitrite may be used in conjunction with sodium thiosulfate; administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). The benefit of sodium thiosulfate in combination with hydroxocobalamin has been questioned; however, cases of favorable outcomes following severe poisonings have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3295013','lexi-content-ref-25645744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3295013','lexi-content-ref-25645744'])">Ref</a></span>). Consider consultation with a clinical toxicologist or poison control center.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a875d214-00d5-418b-b0ba-12ca627c6a85">Calciphylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calciphylaxis (off-label use):</b>
<b>Note:</b> Optimal dose is not established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients on dialysis:</i>
<b>IV: </b>25 g administered 3 times per week during the last hour of or after the hemodialysis session. Continue therapy until there is complete resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17938357','lexi-content-ref-21834598','lexi-content-ref-15168392','lexi-content-ref-23520041','lexi-content-ref-18186845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17938357','lexi-content-ref-21834598','lexi-content-ref-15168392','lexi-content-ref-23520041','lexi-content-ref-18186845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients not on dialysis (normal renal function or mildly reduced GFR):</i>
<b>IV:</b> 25 g administered 3 times per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17310015','lexi-content-ref-18627391']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17310015','lexi-content-ref-18627391'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1436790-f5af-43d5-8b15-c07cd41c0a01">Extravasation management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mechlorethamine: <b>SUBQ</b> (off-label route): Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution (into the extravasation site) for each mg of mechlorethamine suspected to have extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23304728','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23304728','lexi-content-ref-Polovich.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cisplatin, concentrated: Inject 2 mL of a 1/6 M (~4%) sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; consider also injecting 1 mL of a 1/6 M (~4%) sodium thiosulfate solution as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation, may repeat SUBQ injections several times over the next 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bendamustine:<b> SUBQ:</b> Bendamustine extravasation may be managed with 1/6 M (~4%) sodium thiosulfate solution in the same manner as mechlorethamine extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f77ee59-adb9-4ab5-a063-6056770d44cd">Management of delayed calcium extravasation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Management of delayed calcium extravasation (calcinosis cutis) (off-label use): Note:</b> Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 12.5 g over 30 minutes, administered 3 times per week; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990389"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination is significant and risk of adverse effects may be increased in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Calciphylaxis (off-label use): No dosage adjustment necessary. When used for patients not on dialysis (normal renal function or mildly reduced GFR), because sodium thiosulfate is cleared by the kidney, dose may be adjusted based on appearance of adverse effects (eg, metabolic acidosis, hypotension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18627391','lexi-content-ref-23636659','lexi-content-ref-23520041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18627391','lexi-content-ref-23636659','lexi-content-ref-23520041'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987511"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F222279"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for infants, children, and adolescents administered sodium thiosulfate concomitantly with cisplatin, unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypermagnesemia, hypernatremia, hypokalemia, hyponatremia, hypophosphatemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population; sodium thiosulfate may be administered with either cisplatin or sodium nitrite):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Shen 2019), hypocalcemia, metabolic acidosis (Sohal 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Salty taste</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Prolonged bleeding time, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized warm feeling</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Disorientation, headache</p></div>
<div class="block coi drugH1Div" id="F222290"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Pedmark: History of severe hypersensitivity to sodium thiosulfate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F222276"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Pedmark: Hypernatremia and hypokalemia may occur. Do not initiate treatment with baseline serum sodium &gt;145 mmol/L; initiate appropriate treatment as necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Pedmark: Nausea and vomiting may occur. Premedication with antiemetics may be administered; initiate additional antiemetics and supportive care as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Pedmark: Hypersensitivity reactions has been reported. Immediately discontinue treatment and initiate appropriate care as needed if hypersensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In these patients, the induction of methemoglobinemia with amyl nitrite or sodium nitrite is contraindicated until carbon monoxide levels return to normal due to the risk of tissue hypoxia. Methemoglobinemia decreases the oxygen-carrying capacity of hemoglobin and the presence of carbon monoxide prevents hemoglobin from releasing oxygen to the tissues. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. However, hydroxocobalamin is the preferred cyanide antidote and should be considered to avoid the nitrite-related problems and because sodium thiosulfate has a slow onset of action.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfite hypersensitivity: May contain sodium sulfite; sulfite exposure may cause hypersensitivity reactions, including anaphylaxis and life-threatening or severe asthma episodes in susceptible patients. The presence of sulfite hypersensitivity should not preclude the use of this medication when being used for cyanide poisoning.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form considerations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral sodium thiosulfate is available as two separate products with unique indications, concentrations, and dosing which should not be interchanged.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain; however, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Signs of cyanide poisoning may include altered mental status, mydriasis, nausea/vomiting, dyspnea, chest tightness, hyper-/hypotension, plasma lactate ≥8 mmol/L. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Consider consultation with a clinical toxicologist or poison control center. Ototoxicity risk reduction: Safety and efficacy have not been established when administered following cisplatin infusions &gt;6 hours; with cisplatin infusions &gt;6 hours, irreversible ototoxicity may have already occurred and sodium thiosulfate may not reduce this risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Initiation of treatment: Cyanide poisoning: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Return of symptoms: Cyanide poisoning: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24 to 48 hours; repeat treatment (one-half the original dose) should be administered if symptoms return.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F57261735"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Electrolyte abnormalities (hypernatremia, hypokalemia) have been reported in pediatric ototoxicity risk reduction clinical trials. Hypernatremia developed in 12% to 26% of patients, including grade 3 in one patient. A sodium thiosulfate dose of 20 g/m<sup>2</sup> contains 162 mmol/m<sup>2</sup> of sodium, a 15 g/m<sup>2</sup> dose contains 121 mmol/m<sup>2</sup> of sodium, and 10 g/m<sup>2</sup> contains 81 mmol/m<sup>2</sup> of sodium. Do not administer sodium thiosulfate (Pedmark) in patients with serum sodium levels &gt;145 mmol/L. Due to an underdeveloped sodium homeostasis system compared to older infants, use of sodium thiosulfate (Pedmark) is not recommended in neonatal patients. Hypokalemia was reported in 15% to 27% of patients. Patients should be monitored for signs of hypernatremia and hypokalemia and treated and supplemented as needed.</p>
<p style="text-indent:0em;margin-top:2em;">When used to reduce the risk of ototoxicity from cisplatin, there is an increased risk of nausea and vomiting in pediatric patients; antiemetics should be given prior to administration.</p></div>
<div class="block foc drugH1Div" id="F222284"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pedmark: 12.5% (100 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25% [250 mg/mL] (50 mL)</p></div>
<div class="block geq drugH1Div" id="F222272"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323882"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pedmark Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5% (per mL): $137.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sodium Thiosulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/mL (per mL): $2.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868269"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Seacalphyx: 25% [250 mg/mL] (100 mL) [contains disodium edta, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25% [250 mg/mL] (10 mL, 50 mL)</p></div>
<div class="block admp drugH1Div" id="F52613874"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Route of administration dependent upon use.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cisplatin-induced ototoxicity:</b> Pedmark (125 mg/mL): <b>Note:</b> Sodium thiosulfate (Pedmark) can cause nausea and vomiting; antiemetics should be administered prior to treatment. Premedication with antihistamines or glucocorticoids (if appropriate) should be administered to patients with a history of hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:6em;">Administer undiluted by IV infusion over 15 minutes at 6 hours after end of cisplatin infusion. <b>Note:</b> If cisplatin is a multiday regimen, administer at least 10 hours prior to next cisplatin dose if able; however, if subsequent dose due in &lt;10 hours, do not administer sodium thiosulfate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cyanide poisoning:</b> Administer undiluted (25% solution) by IV infusion over 10 to 30 minutes immediately after the administration of sodium nitrite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). Decrease rate of infusion in the event of significant hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> Cisplatin, concentrated: Inject 1/6 M (~4%) sodium thiosulfate solution into the existing IV line in addition to SUBQ injections around extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: <b>Extravasation management:</b> Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula unless treating cisplatin extravasation (for cisplatin extravasation, temporarily keep needle/cannula in place to allow for IV sodium thiosulfate to be administered); elevate extremity.</p>
<p style="text-indent:-2em;margin-left:4em;">Mechlorethamine: Inject SUBQ 1/6 M (~4%) sodium thiosulfate solution into the extravasation site using ≤25-gauge needle; change needle with each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23304728','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23304728','lexi-content-ref-Polovich.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cisplatin, concentrated: Inject SUBQ 1/6 M (~4%) sodium thiosulfate solution clockwise into the area around the extravasation site using a new 25- or 27-gauge needle for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F222287"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Cyanide poisoning: Administer by IV infusion over 10 to 30 minutes. Decrease rate of infusion in the event of significant hypotension. When used with sodium nitrite, administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1'])">Ref</a></span>). If sodium thiosulfate is used in combination with hydroxocobalamin, administer via different IV lines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17098327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17098327'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Calciphylaxis (off-label use): Administer by IV infusion over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15168392','lexi-content-ref-23520041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15168392','lexi-content-ref-23520041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula (temporarily keep in place for cisplatin extravasation to allow for sodium thiosulfate administration through the needle/cannula); elevate extremity.</p>
<p style="text-indent:-2em;margin-left:4em;">Mechlorethamine: Inject SUBQ (off-label route) into the extravasation site using ≤25-gauge needle; change needle with each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23304728','lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23304728','lexi-content-ref-Polovich.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cisplatin, concentrated: Inject into the existing IV line; consider also injecting 1 mL as 0.1 mL SUBQ injections (clockwise) into the area around the extravasation using a new 25- or 27-gauge needle for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Bendamustine: SUBQ: Bendamustine extravasation may be managed with sodium thiosulfate in the same manner as mechlorethamine extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F10076269"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 25 g of sodium thiosulfate be stocked, especially in hospitals that serve industrial areas. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management (off-label use/route): Store the 1/6 M solution for SUBQ administration at 15°C to 30°C (59°F to 86°F) (Polovich 2009).</p></div>
<div class="block usep drugH1Div" id="F53568931"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">To reduce the risk of ototoxicity associated with cisplatin treatment of nonmetastasized, localized solid tumors following cisplatin infusions ≤6 hours duration (Pedmark: FDA approved in pediatric patients ≥1 month of age).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of acute cyanide poisoning considered to be serious or life-threatening (250 mg/mL solution: FDA approved in pediatric patients [age not specified] and adults); has also been used for the management of mechlorethamine extravasation, management of concentrated cisplatin (≥0.4 mg/mL) extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note</b>
<b>: </b>The preferred antidote for the treatment of acute cyanide poisoning is hydroxocobalamin, especially in patients who have concurrent carbon monoxide poisoning (eg, smoke inhalation), significant anemia, or G6PD deficiency (Anseeuw 2013; Mintegi 2013). Sodium nitrite and sodium thiosulfate should be considered only if hydroxocobalamin is unavailable, there is a contraindication to the use of hydroxocobalamin, or if the patient has a known sensitivity to hydroxocobalamin or vitamin B<sub>12</sub> analogues. Sodium thiosulfate is <b>not</b> generally used as the sole intervention for cyanide toxicity, as it has a delayed onset of action, small V<sub>d</sub>, and short half-life. Consider consultation with a poison control center.</p></div>
<div class="block cyt drugH1Div" id="F13300072"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223035"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F222293"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cyanide crosses the placenta; untreated cyanide poisoning can be fatal to the mother and fetus.</p>
<p style="text-indent:0em;margin-top:2em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). However, other treatments may be preferred for the treatment of cyanide toxicity during pregnancy (Culnan 2018; Roderique 2012).</p></div>
<div class="block mopp drugH1Div" id="F53568914"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Cisplatin-induced ototoxicity: Monitor serum sodium and potassium (baseline, prior to each dose, and periodically), signs and symptoms of hypernatremia or hypokalemia, hypersensitivity reactions, and nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Cyanide poisoning: Monitor for adequate oxygenation and perfusion and for recurrent signs and symptoms of cyanide toxicity for at least 24 to 48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO<sub>2</sub> gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management: Monitor and document extravasation site for pain, blister formation, skin sloughing, arm/hand swelling/stiffness; monitor for fever, chills, or worsening pain.</p></div>
<div class="block pha drugH1Div" id="F222275"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Cyanide toxicity: Serves as a sulfur donor in rhodanese-catalyzed formation of thiocyanate (much less toxic than cyanide).</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management: Neutralizes the reactive species of mechlorethamine; reduces the formation of hydroxyl radicals which cause tissue injury.</p>
<p style="text-indent:-2em;margin-left:2em;">Cisplatin ototoxicity: Neutralizes cisplatin to produce an inactive platinum complex.</p></div>
<div class="block phk drugH1Div" id="F222289"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Thiosulfate:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients ≥1 month of age: 0.23 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.15 L/kg (Howland 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Thiocyanate: 0.25 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Thiosulfate:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients ≥1 month of age: 20 to 50 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~3 hours (Howland 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Thiocyanate: 2.7 days; prolonged with renal impairment to ~9 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients ≥1 month of age: Urine (approximately 50% thiosulfate as unchanged drug, &gt;95% within the first 4 hours after administration).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Urine (~20% to 50% thiosulfate as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038829"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Natriumthiosulfat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hospira sodium thiosulphate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Tiosulfato de sodio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Natriumthiosulfat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Natriumthiosulfat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hyposulfene | Natriumthiosulfat</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Natriumthiosulfat/dr. franz kohler chemie</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pedmarqsi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sodio Tiosolf Sal | Sodio tiosolfato</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Detoxol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ametox | Thiosulfate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Natrium thiosulfas</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Natrii thiosulfas | Natrium thiosulfas</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sodium thiosulphat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Natrium thiosulfatum | Natriumthiosulfat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Natrium thiosulfas | Sodium thiosulphate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Sodium thiosulphate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Detoxol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17938357">
<a name="17938357"></a>Ackermann F, Levy A, Daugas E, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. <i>Arch Dermatol</i>. 2007;143(10):1336-1337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/17938357/pubmed" id="17938357" target="_blank">17938357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22828651">
<a name="22828651"></a>Anseeuw K, Delvau N, Burillo-Putze G, et al. Cyanide poisoning by fire smoke inhalation: a European expert consensus. <i>Eur J Emerg Med</i>. 2013;20(1):2-9. doi:10.1097/MEJ.0b013e328357170b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/22828651/pubmed" id="22828651" target="_blank">22828651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21834598">
<a name="21834598"></a>Auriemma M, Carbone A, Di Liberato L, . Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature. <i>Am J Clin Dermatol</i>. 2011;12(5):339-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/21834598/pubmed" id="21834598" target="_blank">21834598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATSDR.1">
<a name="ATSDR.1"></a>Agency for Toxic Substances and Disease Registry (ATSDR), “Medical Management Guidelines for Hydrogen Cyanide (HCN).” Available at <a href="https://www.atsdr.cdc.gov/MHMI/mmg8.pdf" target="_blank">http://www.atsdr.cdc.gov/MHMI/mmg8.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10864222">
<a name="10864222"></a>Albanell J and Baselga J, "Systemic Therapy Emergencies," <i>Semin Oncol</i>, 2000, 27(3):347-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/10864222/pubmed" id="10864222" target="_blank">10864222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17310015">
<a name="17310015"></a>Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. <i>Arch Dermatol</i>. 2007;143(2):269-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/17310015/pubmed" id="17310015" target="_blank">17310015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20511644">
<a name="20511644"></a>Bebarta VS, Pitotti RL, Borys DJ, et al, “Seven Years of Cyanide Ingestions in the USA: Critically Ill Patients are Common, but Antidote Use is Not,” <i>Emerg Med J</i>, 2011, 28(2):155-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/20511644/pubmed" id="20511644" target="_blank">20511644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924955">
<a name="29924955"></a>Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. <i>N Engl J Med</i>. 2018;378(25):2376-2385. doi:10.1056/NEJMoa1801109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/29924955/pubmed" id="29924955" target="_blank">29924955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15168392">
<a name="15168392"></a>Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. <i>Am J Kidney Dis</i>. 2004;43(6):1104-1108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/15168392/pubmed" id="15168392" target="_blank">15168392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29461288">
<a name="29461288"></a>Culnan DM, Craft-Coffman B, Bitz GH, et al. Carbon monoxide and cyanide poisoning in the burned pregnant patient: an indication for hyperbaric oxygen therapy. <i>Ann Plast Surg</i>. 2018;80(3)(suppl 2):S106-S112. doi:10.1097/SAP.0000000000001351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/29461288/pubmed" id="29461288" target="_blank">29461288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28494173">
<a name="28494173"></a>De Capitani EM, Borrasca-Fernandes CF, Branco Pimenta M, et al. Suicide attempt with acetonitrile ingestion in a nursing mother. <i>Clin Toxicol (Phila)</i>. 2017;55(8):929-933. doi:10.1080/15563650.2017.1324977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/28494173/pubmed" id="28494173" target="_blank">28494173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2182147">
<a name="2182147"></a>Dorr RT, "Antidotes to Vesicant Chemotherapy Extravasations," <i>Blood Rev</i>, 1990, 4(1):41-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/2182147/pubmed" id="2182147" target="_blank">2182147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151940">
<a name="15151940"></a>Ener RA, Meglathery SB, and Styler M, "Extravasation of Systemic Hemato-oncological Therapies," <i>Ann Oncol</i>, 2004, 15(6):858-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/15151940/pubmed" id="15151940" target="_blank">15151940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31866182">
<a name="31866182"></a>Freyer DR, Brock PR, Chang KW, et al. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. <i>Lancet Child Adolesc Health</i>. 2020;4(2):141-150. doi:10.1016/S2352-4642(19)30336-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/31866182/pubmed" id="31866182" target="_blank">31866182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27914822">
<a name="27914822"></a>Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2017;18(1):63-74. doi:10.1016/S1470-2045(16)30625-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/27914822/pubmed" id="27914822" target="_blank">27914822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15628833">
<a name="15628833"></a>Gracia R and Shepherd G, "Cyanide Poisoning and Its Treatment," <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/15628833/pubmed" id="15628833" target="_blank">15628833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627391">
<a name="18627391"></a>Hackett BC, McAleer MA, Sheehan G, Powell FC, O'Donnell BF. Calciphylaxis in a patient with normal renal function: response to treatment with sodium thiosulfate. <i>Clin Exp Dermatol</i>. 2009;34(1):39-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/18627391/pubmed" id="18627391" target="_blank">18627391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17098327">
<a name="17098327"></a>Hall AH, Dart R, Bogdan G. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning?<i> Ann Emerg Med</i>. 2007;49(6):806-813. doi:10.1016/j.annemergmed.2006.09.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/17098327/pubmed" id="17098327" target="_blank">17098327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3295013">
<a name="3295013"></a>Hall AH, Rumack BH. Hydroxycobalamin/sodium thiosulfate as a cyanide antidote. <i>J Emerg Med</i>. 1987;5(2):115-121. doi:10.1016/0736-4679(87)90074-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/3295013/pubmed" id="3295013" target="_blank">3295013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holstege.1">
<a name="Holstege.1"></a>Holstege CP, Kirk MA. Cyanide and hydrogen sulfide. In: Nelson LS, Howland, MA, Lewin NA, et al, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. McGraw-Hill Education; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland MA. Antidotes in depth: nitrites (amyl and sodium) and sodium thiosulfate. In: Nelson LS, Howland, MA, Lewin NA, et al, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. McGraw-Hill Education; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636659">
<a name="23636659"></a>Mao M, Lee S, Kashani K, Albright R, Qian Q. Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. <i>J Med Toxicol.</i> 2013;9(3):274-277. doi:10.1007/s13181-013-0305-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/23636659/pubmed" id="23636659" target="_blank">23636659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24196100">
<a name="24196100"></a>Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. <i>Pediatr Emerg Care</i>. 2013;29(11):1234-1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/24196100/pubmed" id="24196100" target="_blank">24196100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” <i>Chest</i>, 2003, 123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23520041">
<a name="23520041"></a>Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. <i>Clin J Am Soc Nephrol</i>. 2013;8(7):1162-1170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/23520041/pubmed" id="23520041" target="_blank">23520041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pedmark.1">
<a name="Pedmark.1"></a>Pedmark (sodium thiosulfate) [prescribing information]. Hoboken, NJ: Fennec Pharmaceuticals Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28603903">
<a name="28603903"></a>Peng T, Zhuo L, Wang Y, et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. <i>Nephrology (Carlton).</i> 2018;23(7):669-675. doi:10.1111/nep.13081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/28603903/pubmed" id="28603903" target="_blank">28603903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23304728">
<a name="23304728"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, "Management of Chemotherapy Extravasation: ESMO--EONS Clinical Practice Guidelines," <i>Eur J Oncol Nurs</i>, 2012, 16(5):528-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/23304728/pubmed" id="23304728" target="_blank">23304728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.1">
<a name="Polovich.1"></a>Polovich M, Whitford JN and Olsen M, <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22672162">
<a name="22672162"></a>Reade MC, Davies SR, Morley PT, et al, “Review Article: Management of Cyanide Poisoning,” <i>Emerg Med Australas</i>, 2012, 24(3):225-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/22672162/pubmed" id="22672162" target="_blank">22672162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22293595">
<a name="22293595"></a>Roderique EJ, Gebre-Giorgis AA, Stewart DH, Feldman MJ, Pozez AL. Smoke inhalation injury in a pregnant patient: a literature review of the evidence and current best practices in the setting of a classic case. <i>J Burn Care Res</i>. 2012;33(5):624-633. doi:10.1097/BCR.0b013e31824799d2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/22293595/pubmed" id="22293595" target="_blank">22293595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L, "Extravasation Management: Clinical Update," <i>Semin Oncol Nurs</i>, 2011, 27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31111826">
<a name="31111826"></a>Shen C, Zhou Y, Chen Z, Rao L. Hypercalcemia associated with sodium thiosulfate treatment in a patient with calciphylaxis. <i>Pol Arch Intern Med</i>. 2019;129(9):638-640. doi:10.20452/pamw.14837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/31111826/pubmed" id="31111826" target="_blank">31111826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hope.1">
<a name="Hope.1"></a>Sodium thiosulfate [prescribing information]. Scottsdale, AZ: Hope Pharmaceuticals; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32336746">
<a name="32336746"></a>Sohal R, George T. Sodium-thiosulfate induced life-threatening metabolic acidosis limiting treatment of calciphylaxis. <i>Am J Case Rep</i>. 2020;21:e919926. doi:10.12659/AJCR.919926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/32336746/pubmed" id="32336746" target="_blank">32336746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18186845">
<a name="18186845"></a>Subramaniam K, Wallace H, Sinniah R, Saker B. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. <i>Australas J Dermatol</i>. 2008;49(1):30-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/18186845/pubmed" id="18186845" target="_blank">18186845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23163594">
<a name="23163594"></a>Thompson JP and Marrs TC, “Hydroxocobalamin in Cyanide Poisoning,” <i>Clin Toxicol</i>, 2012, 50(10):875-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/23163594/pubmed" id="23163594" target="_blank">23163594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25645744">
<a name="25645744"></a>Zakharov S, Vaneckova M, Seidl Z, et al. Successful use of hydroxocobalamin and sodium thiosulfate in acute cyanide poisoning: a case report with follow-up. <i>Basic Clin Pharmacol Toxicol.</i> 2015;117(3):209-212. doi:10.1111/bcpt.12387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/25645744/pubmed" id="25645744" target="_blank">25645744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23291368">
<a name="23291368"></a>Zitt E, König M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. <i>Nephrol Dial Transplant</i>. 2013;28(5):1232–1240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-thiosulfate-pediatric-drug-information/abstract-text/23291368/pubmed" id="23291368" target="_blank">23291368</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12800 Version 135.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
